Back
Avenue Therapeutics 10K Form
Sell
13
ATXI
Avenue Therapeutics
Last Price:
6.06
Seasonality Move:
-7.19%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
10K form not available
Receive ATXI News And Ratings
See the #1 stock for the next 7 days that we like better than ATXI
ATXI Financial Statistics
Sales & Book Value
| Annual Sales: | -- |
|---|---|
| Cash Flow: | $-2.32M |
| Price / Cash Flow: | 0 |
| Annual Sales: | $4.64 |
| Price / Book: | 2.31 |
Profitability
| EPS (TTM): | -285.74980 |
|---|---|
| Net Income (TTM): | $-10.38M |
| Gross Margin: | -- |
| Return on Equity: | 0% |
| Return on Assets: | 0% |
Avenue Therapeutics Earnings Forecast
Key Avenue Therapeutics Financial Ratios
- The Interest Expense is -3.20% of Operating Income.
- Per Share Earnings over the last 8 years have been positive in 5 years.
Avenue Therapeutics Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Current Symbol: | ATXI |
| CUSIP: | 05360L |
| Website: | avenuetx.com |
Debt
| Debt-to-Equity Ratio: | 0 |
|---|---|
| Current Ratio: | 0 |
| Quick Ratio: | 0 |
Price-to-Earnings
| Trailing P/E Ratio: | 0 |
|---|---|
| Forward P/E Ratio: | 0 |
ATXI Technical Analysis vs Fundamental Analysis
Sell
13
Avenue Therapeutics (ATXI)
is a Sell
Is Avenue Therapeutics a Buy or a Sell?
-
Avenue Therapeutics stock is rated a Sell
The current Avenue Therapeutics [ATXI] share price is $6.20. The Score for ATXI is 13, which is 74% below its historic median score of 50, and infers higher risk than normal.